Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 524

Sort by

Sort Order Select

Journal Articles

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD

Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Alessandra Ferrajoli, Nitin Jain, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger

Blood blood.2024025683.

https://doi.org/10.1182/blood.2024025683

Published: 2024

Includes: Supplemental data

Journal Articles

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, David Radtke, Sonya Chapman, Narasimha Marella, Samuel C. McNeely, Jennifer R. Brown

Blood (2024) 144 (13): 1374–1386.

https://doi.org/10.1182/blood.2024024510

Published: 2024

Includes: Supplemental data

Journal Articles

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Philip A. Thompson, Alexandre Bazinet, William G. Wierda, Constantine S. Tam, Susan M. O’Brien, Satabdi Saha, Christine B. Peterson, William Plunkett, Michael J. Keating

Blood (2023) 142 (21): 1784–1788.

https://doi.org/10.1182/blood.2023020158

Published: 2023

Includes: Supplemental data

Journal Articles

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Blood (2023) 142 (Supplement 1): 636.

https://doi.org/10.1182/blood-2023-174750

Published: 2023

Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 325.

https://doi.org/10.1182/blood-2023-185852

Published: 2023

Journal Articles

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4289.

https://doi.org/10.1182/blood-2023-182901

Published: 2023

Journal Articles

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Paolo Ghia, William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan, Zoë Hunter, Cathy Zhou, Anita Szoke, James P. Dean, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 633.

https://doi.org/10.1182/blood-2023-187128

Published: 2023

Journal Articles

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Nitin Jain, James D'Olimpio, Andew gillis-Smith, Seung Tae Lee, Nirav N. Shah, Javier Pinilla-Ibarz, Catherine C. Coombs, Jacqueline C. Barrientos, Shuo Ma, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, Varsha Gandhi, William G. Wierda

Blood (2023) 142 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2023-182568

Published: 2023

Journal Articles

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Daisy Diaz Rohena, Arnau Peris Cuesta, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Charmelle Williams, Wanyi Hu, Peiyi Zhang, Philip Thompson, William G. Wierda, Nitin Jain, Sachet Shukla, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2023) 142 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2023-188250

Published: 2023

Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2023-181108

Published: 2023

Journal Articles

Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study

Eniko Papp, Sahar Ansari, Jason Wall, Ethan Thompson, Yizhe Chen, Tanya Siddiqi, William G. Wierda, Serena K. Perna, Sherilyn A. Tuazon, Abood Okal, Leanne Peiser

Blood (2023) 142 (Supplement 1): 3263.

https://doi.org/10.1182/blood-2023-180230

Published: 2023

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C Coombs, Nirav N. Shah, William G. Wierda, Manish Patel, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Narasimha Marella, Caleb Ho, Samuel McNeely, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2023-181090

Published: 2023

Journal Articles

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Blood (2023) 142 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2023-173992

Published: 2023

Journal Articles

MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL

Jyotsana Singh, John R. Sanchez II, Chaomei Liu, Bailey Slawin, Nitin Jain, William G. Wierda, Kai Zhang, Michael Niesman, James S. Blachly, Jennifer A. Woyach, Deepa Sampath

Blood (2023) 142 (Supplement 1): 2283.

https://doi.org/10.1182/blood-2023-189378

Published: 2023

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Blood (2023) 142 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2023-179872

Published: 2023

Journal Articles

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 497.

https://doi.org/10.1182/blood-2023-182114

Published: 2023

Journal Articles

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Alex Bataller, Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, William G. Wierda, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4228.

https://doi.org/10.1182/blood-2023-182841

Published: 2023

Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial

Jan A. Burger, Ekaterina Kim, Mariela Sivina, Thomas Mathew, Danielle E. Hammond, Fadi G. Haddad, Alessandra Ferrajoli, William G. Wierda

Blood (2023) 142 (Supplement 1): 6524.

https://doi.org/10.1182/blood-2023-178774

Published: 2023

NARROW

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only